Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Jan 31;14(3):735. doi: 10.3390/cancers14030735

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

Rat glioblastoma C6 growth inhibition mediated by human yCD::UPRT-MSC-exos/5-FC conjugates in vivo. Tumors were induced by 5 × 10⁵ or 1 × 10⁶ C6 cells inoculated intracerebrally. (a) Survival of rats bearing 5 × 10⁵ intracerebral C6 glioblastoma cells treated with yCD::UPRT-DP-MSC-exos/5-FC conjugate, yCD::UPRT-UC-MSC-exos/5-FC conjugate, and yCD::UPRT-AT- MSC-exos/5-FC conjugate applied s.c., i.n., and i.p. (b) Survival of rats bearing 1 × 10⁶ intracerebral C6 glioblastoma cells treated with yCD::UPRT-DP-MSC-exos/5-FC conjugate by i.n. application (every day) and yCD::UPRT-UC-MSC-exos/5-FC conjugate applied i.p. three times per week (c) Course of body weights of treated and untreated animals during the experiment. (d) MRI examinations of treated animals during the course of treatment and final histopathological examinations. 5-FC, 5-fluorocytosine; MRI—magnetic resonance imaging.